The EPIC-B trial demonstrates the efficacy of cemiplimab monotherapy as a treatment for locally advanced or metastatic penile cancer (la/mPC). The trial met its primary endpoint, with a clinical ...

New research from The Lancet highlights persistent symptoms after the flu, similar to 'long Covid.' Veterans studied faced ...

Q3 2025 Earnings Call Transcript February 13, 2025 Operator: And good day. Thank you for standing by. Welcome to VistaGen ...

Review of data from the trial found that the vaccine was not sufficiently effective at preventing invasive E coli disease ...

Gene Mack, Gain Therapeutics CEO, provides a look into the future of the company and the use of physics-based artificial ...

Positive IHL-42X PK findings for the treatment of Obstructive Sleep Apnea (OSA) support future 505(b)(2) New Drug Application (NDA) submissionNew OSA Clinical Advisory Board Announced; Appoints Dr. Al ...

EXCLUSIVE: Retired David Mather was dealt a shocking blow when told his tiredness was stage-IV lung cancer - now a new UK ...

Reports fourth quarter revenues of $1.0 billion, GAAP net loss of $(1.1) billion and GAAP EPS of $(2.91); loss includes approximately $0.2 billion of non-cash charges related to manufacturing resizing ...

There exists no ‘amyloid cabal’” in Alzheimer’s research, neurologist Dennis Selkoe writes in response to Charles Piller’s ...

Vistagen Therapeutics' Q3 2025 earnings reveal progress on Phase 3 trials for social anxiety drug fasedienol, innovative therapies, and strong ...